Skin reactions - Chronic Myeloid Leukemia - CML
ARTICLES
Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia
September 21, 2023, Cureus
Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
August 26, 2019, Dovepress
Cutaneous manifestations of Nilotinib
June 20, 2018, Symbiosis
Nilotinib case series induced skin rash in chronic myeloid leukemia patients: A
November 1, 2016, International Journal of Medical Science and Public Health
Cancer Drug Linked to Case of Scurvy
May 11, 2016, Monthly Prescribing Reference
Nilotinib-Induced Keratosis Pilaris
April 2016, NCBI
Multiple squamous cell carcinomas following introduction of nilotinib
August 22, 2014, Wiley Online Library
Hypopigmentation of the Skin and Hair. Associated with Targeted Therapies
2014, Journal of Cancerology
Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
November 1, 2013, JAAD
46-Year-Old CML Patient Develops Painful Ulceration
September 10, 2012, Cancer Network
Mucosal Pigmentation Caused by Imatinib: Report of Three Cases
December 31, 2011, NCBI
Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib
2011, Dermatologic Therapy, Vol. 24, 2011, 386–395
Leukemia Cutis
June 2010, Indian Journal of Dermatology
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.
2009, PubLMed
Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour.
February 2009, PublMed
Skin reactions with imatinib in CML patients: An Indian experience
2006, Journal of Clinical Oncology
Leukemia cutis resembling a flare-up of psoriasis
2006, Dermatology Online Journal
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
February 2004, Oxford Journals
Imatinib mesylate causes hypopigmentation in the skin
December 1, 2003, PubMed
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
February 2003, PublMed
Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia
September 21, 2023, Cureus
Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
August 26, 2019, Dovepress
Cutaneous manifestations of Nilotinib
June 20, 2018, Symbiosis
Nilotinib case series induced skin rash in chronic myeloid leukemia patients: A
November 1, 2016, International Journal of Medical Science and Public Health
Cancer Drug Linked to Case of Scurvy
May 11, 2016, Monthly Prescribing Reference
Nilotinib-Induced Keratosis Pilaris
April 2016, NCBI
Multiple squamous cell carcinomas following introduction of nilotinib
August 22, 2014, Wiley Online Library
Hypopigmentation of the Skin and Hair. Associated with Targeted Therapies
2014, Journal of Cancerology
Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
November 1, 2013, JAAD
46-Year-Old CML Patient Develops Painful Ulceration
September 10, 2012, Cancer Network
Mucosal Pigmentation Caused by Imatinib: Report of Three Cases
December 31, 2011, NCBI
Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib
2011, Dermatologic Therapy, Vol. 24, 2011, 386–395
Leukemia Cutis
June 2010, Indian Journal of Dermatology
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.
2009, PubLMed
Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour.
February 2009, PublMed
Skin reactions with imatinib in CML patients: An Indian experience
2006, Journal of Clinical Oncology
Leukemia cutis resembling a flare-up of psoriasis
2006, Dermatology Online Journal
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
February 2004, Oxford Journals
Imatinib mesylate causes hypopigmentation in the skin
December 1, 2003, PubMed
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
February 2003, PublMed
